- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05803811
Effect van door de dikke darm geleverde vitamine B2 op de darmmicrobiota en gerelateerde gezondheidsbiomarkers bij gezonde oudere volwassenen
The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Cork, Ierland
- Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
- Between 50 and 70 years of age.
- Has a BMI of between 18.5 - 30 Kg/m2.
- Participants have had a stable body weight (≤5 % change) over the past 3-months.
- Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
- Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
- Maintain current level of physical activity.
- Willing to consume the investigational product daily for the duration of the study.
- Female participants in menopause for at least the last one year. -
Exclusion Criteria:
-
Are hypersensitive to any of the components of the test product.
-
Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)
-
Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.
-
Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).
-
Is a smoker or vaper.
-
Vegetarian or vegan.
-
Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).
-
Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
-
Has a currently active eating disorder.
-
Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.
-
Is having a typical fibre intake >30 g fibre/day.
-
Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.
-
If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.
-
Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.
-
Has a current or history of any gastrointestinal cancer
-
Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).
-
Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).
-
Have a current malignant disease or any concomitant end-stage organ disease.
-
Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
-
Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
-
Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.
-
If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).
-
Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).
-
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Low dose
Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Experimenteel: Mid dose
Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Experimenteel: high dose
Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Placebo-vergelijker: Placebo
One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Faecal microbial composition
Tijdsspanne: from baseline to 12 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12 |
from baseline to 12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Alpha diversity
Tijdsspanne: from baseline to 12 weeks
|
Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12. |
from baseline to 12 weeks
|
|
Beta diversity
Tijdsspanne: week 0 to week 12
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12 |
week 0 to week 12
|
|
Faecal microbial metabolites fatty acid content at baseline and week 12
Tijdsspanne: from baseline to 12 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12 |
from baseline to 12 weeks
|
|
Acetate, Propionate and Butyrate
Tijdsspanne: baseline and week 12
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12. |
baseline and week 12
|
|
Intestinal inflammation
Tijdsspanne: from baseline to 12 weeks
|
Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12 |
from baseline to 12 weeks
|
|
Intestinal barrier integrity
Tijdsspanne: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Oxidative stress in blood
Tijdsspanne: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Inflammatory status in blood
Tijdsspanne: from baseline to 12 weeks
|
Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12. |
from baseline to 12 weeks
|
|
Gastrointestinal symptoms
Tijdsspanne: from baseline to 12 weeks
|
Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12. |
from baseline to 12 weeks
|
|
health-related quality of life
Tijdsspanne: from baseline to 12 weeks
|
Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase. |
from baseline to 12 weeks
|
|
Stool consistency
Tijdsspanne: from baseline to 12 weeks
|
Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively. |
from baseline to 12 weeks
|
|
Stool frequency
Tijdsspanne: from baseline to 12 weeks
|
Stool frequency, as reported in the daily eDiary app (at baseline and week 12). |
from baseline to 12 weeks
|
|
Systemic vitamin status
Tijdsspanne: from baseline to 12 weeks
|
The concentration of B vitamins in blood at baseline |
from baseline to 12 weeks
|
|
Faecal physiological pH and redox
Tijdsspanne: from baseline to 12 weeks
|
Faecal physiological parameters measured as pH and redox potential at baseline and at week 12. |
from baseline to 12 weeks
|
|
Faecal microbial composition at week 4
Tijdsspanne: from baseline to 4 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4. |
from baseline to 4 weeks
|
|
Alpha diversity at week 4
Tijdsspanne: baseline to Week 4.
|
Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4. |
baseline to Week 4.
|
|
Beta diversity at week 4
Tijdsspanne: week 0 to week 4
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4 |
week 0 to week 4
|
|
Microbial metabolites at week 4
Tijdsspanne: from baseline to 4 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4. |
from baseline to 4 weeks
|
|
Acetate, Propionate and Butyrate at week 4
Tijdsspanne: week 0 to week 4
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4. |
week 0 to week 4
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Skin barrier integrity
Tijdsspanne: from baseline to 12 weeks
|
Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12. |
from baseline to 12 weeks
|
|
Skin hydration
Tijdsspanne: from baseline to 12 weeks
|
Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12. |
from baseline to 12 weeks
|
|
Objective skin-health
Tijdsspanne: from baseline to 12 weeks
|
Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12. |
from baseline to 12 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Prof Timothy Dinan, Cork University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2020-11-11-VITB2
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .